Foundation Medicine, Inc.
http://www.foundationmedicine.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Foundation Medicine, Inc.
The Real World Is Not Enough: Comparability Is Common Obstacle For RWE In US FDA Decisions
Unsuccessful attempts to use real-world evidence for approvals highlight the need to demonstrate relationship between real-world data and clinical trial patients. The Pink Sheet examines what went wrong for Bluebird/Bristol’s Abecma, Ultragenyx’s Dojolvi, and Karyopharm’s Xpovio.
Keeping Track: US FDA Clears New Uses For Incyte’s Pemazyre, AbbVie’s Imbruvica; Minerva Seeks First Negative Symptoms Claim In Schizophrenia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
FoundationOne Nabs US FDA Approval As Companion Diagnostic For Rare Cancers
The approval is the 25th indication for the diagnostic, but the first for any companion diagnostic to Roche’s Rozlytrek.
AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza
Deal Snapshot: Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.
Company Information
- Industry
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics